Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

Extract

Funding sources: this study was financially supported by Novartis. Novartis was not involved in the collection, management, analysis, preparation, approval of the manuscript or decision to submit the manuscript for publication.

Conflicts of interest: A.B.G. has served as a consultant and advisory board member for Janssen Inc; Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, AbbVie, UCB, Novartis, Incyte, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries and has received research and educational grants from Novartis, Lilly, Leo, Allergan, Janssen and Incyte. D.R. has received honoraria as a consultant for AbbVie, Celgene, Dermavant, Janssen, Lilly, Novartis, Pfizer and Regeneron Pharmaceuticals Inc; has received research support from AbbVie, Bristol Meyers Squibb, Celgene, Dermira, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer and Regeneron Pharmaceuticals Inc; and has served as a paid speaker for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc and Sanofi.

Dear Editor, Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the apocrine gland‐rich intertriginous areas.1 HS lesions have an elevated T helper (Th)17 immune response, and it is often challenging to treat patients, with existing therapies having limited efficacy.2,3 We sought to investigate the role of secukinumab, a human monoclonal antibody that inhibits interleukin (IL)‐17A, in HS treatment.